Search Results for: "Clinic Roundup"
-
Clinic Roundup
No serious adverse events were reportedBioWorld Today | Wednesday, March 20, 2013 -
Pharma: Clinic Roundup
The most common treatment-emergent adverse events were headache, indigestion and back painBioWorld Today | Tuesday, March 19, 2013 -
Clinic Roundup
Data also showed that no new safety signals were observed with repeat dosing and the types of adverse events were consistent with those reported in earlier studiesBioWorld Today | Monday, March 18, 2013 -
Clinic Roundup
The drug was also well tolerated, with similar rates of occurrence of serious adverse events among drug and placebo groups...There were no product-related serious adverse events in either armBioWorld Today | Friday, March 15, 2013 -
Pharma: Clinic Roundup
In addition, statistically significant increases in non-fatal serious adverse events (SAE) were observed in patients on Tredaptive plus statin therapy compared to placebo plus statin therapy...Adverse events were consistent with those already known for eplerenone, primarily hyperkalemiaBioWorld Today | Tuesday, March 12, 2013 -
Clinic Roundup
The rate of serious adverse events and the rate of discontinuations due to adverse events were similar between the two groupsBioWorld Today | Tuesday, March 12, 2013 -
Clinic Roundup
Adverse events reported in the study were generally mild or moderate in nature and similar in both placebo and treatment groupsBioWorld Today | Wednesday, March 6, 2013 -
Clinic Roundup
Adverse events were mild, predictable and manageable...VX-787 was generally well tolerated, with no adverse events leading to discontinuationBioWorld Today | Tuesday, March 5, 2013 -
Pharma: Clinic Roundup
Adverse event (AE) profiles were similar between the two treatment groups and consistent with known AEs associated with progesteroneBioWorld Today | Tuesday, March 5, 2013 -
Clinic Roundup
The committee reviewed the treatment effect at one year on the primary outcome measure of efficacy, change in motor function using the MFM scale, together with the latest safety report, including electrocardiogram traces, periodic laboratory findings, hemostatic parameters and serious adverse events listings for all participantsBioWorld Today | Friday, March 1, 2013 -
Clinic Roundup
However, preliminary safety data analyses suggested the benefit/risk ratio might not favor the trabedersen treatment arm due to serious adverse events associated with the local mode of administration, so the company will focus on systemic intravenous administration of trabedersen in glioma...The trial reported no imbalance in serious adverse events, and there were a low number of major adverse cardiovascular eventsBioWorld Today | Wednesday, February 27, 2013 -
Pharma: Clinic Roundup
The adverse event profile was consistent with that known for Lyrica, with the most common adverse events including headache, dizziness, insomnia, somnolence, nausea and fatigueBioWorld Today | Friday, February 22, 2013 -
Clinic Roundup
The primary objectives include the evaluation of adverse events and the evaluation of six-month clinical response...The drug was well tolerated, with no significant differences in adverse events between the trial armsBioWorld Today | Wednesday, February 20, 2013 -
Clinic Roundup
Results showed no confirmed VTEs, and the rate of adverse events was similar to those found in pregnant patients during and immediately after delivery...There were also no adverse events among neonatesBioWorld Today | Tuesday, February 19, 2013 -
Clinic Roundup
The most commonly reported adverse events were anorexia and fatigueBioWorld Today | Friday, February 15, 2013 -
Clinic Roundup
No serious adverse events or safety concerns were identifiedBioWorld Today | Tuesday, February 12, 2013 -
Clinic Roundup
The most common adverse events reported in the double-blind, placebo-controlled IMPRESS trials were hematoma, pain and swelling at the treatment siteBioWorld Today | Tuesday, February 5, 2013 -
Clinic Roundup
A similar incidence of grade 3 or higher adverse events was seen in both arms of the trial (28 percent placebo; 27 percent NeulastaBioWorld Today | Tuesday, January 29, 2013 -
Clinic Roundup
There were no significant differences in the adverse event profiles between the three groupsBioWorld Today | Friday, January 25, 2013 -
Clinic Roundup
Preliminary results from the 249-patient study indicated no unexpected adverse events and a favorable tolerability profile...No significant adverse events related to the drug occurred, and Nymox said NX-1207 treatment for BPH was not associated with the sexual, cardiovascular or other side effects associated with approved BPH medicationsBioWorld Today | Wednesday, January 23, 2013
Category
BioWorld | 3525 Piedmont Road
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Part of Thompson Media Group LLC
Free Ezine
Sign up for Perspectives FREE e-mail newsletter.
Customer Service: In the U.S. and Canada: 1-800-477-6307
Outside the U.S.: 1-404-262-5423
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Outside the U.S.: 1-404-262-5423
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Copyright @ 2013 AHC Media. Reproduction, reposting content is strictly prohibited.